Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties.
CI-920 (PD 110,161) and two analogues (PD 113,270 and PD 113,271) are novel antitumor compounds produced by a new actinomycete characterized as Streptomyces pulveraceus subsp. fostreus ATCC 31906. The antitumor compounds are predominantly produced during the stationary (idiophase) growth phase of the organism. CI-920 is active versus the murine P388 lymphocytic and L1210 lymphoid leukemia with T/C values of 246 and 207, respectively. This compound has no significant antimicrobial activity.
D000475:Alkenes / Q000302:isolation & purification / Q000633:toxicity; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000302:isolation & purification*; D004353:Drug Evaluation, Preclinical; D005285:Fermentation; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D051379:Mice; D008826:Microbial Sensitivity Tests; D011090:Polyenes; D011753:Pyrones; D013302:Streptomyces / Q000254:growth & development*; D013329:Structure-Activity Relationship
D000475:Alkenes; D000903:Antibiotics, Antineoplastic; D011090:Polyenes; D011753:Pyrones; C040314:PD 113270; C040315:PD 113271; C040313:fostriecin